Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 11, 2023

SELL
$117.53 - $155.99 $218,253 - $289,673
-1,857 Reduced 31.78%
3,986 $549,000
Q3 2022

Nov 10, 2022

BUY
$75.71 - $119.24 $84,416 - $132,952
1,115 Added 23.58%
5,843 $646,000
Q2 2022

Aug 02, 2022

SELL
$62.69 - $88.44 $3,573 - $5,041
-57 Reduced 1.19%
4,728 $354,000
Q1 2022

May 12, 2022

SELL
$63.15 - $90.42 $15,345 - $21,972
-243 Reduced 4.83%
4,785 $374,000
Q4 2021

Feb 03, 2022

BUY
$77.28 - $99.42 $208,578 - $268,334
2,699 Added 115.89%
5,028 $453,000
Q3 2021

Nov 12, 2021

BUY
$65.97 - $92.48 $153,644 - $215,385
2,329 New
2,329 $215,000
Q2 2021

Aug 13, 2021

SELL
$69.38 - $86.75 $216,812 - $271,093
-3,125 Closed
0 $0
Q1 2021

May 10, 2021

SELL
$72.25 - $168.95 $149,340 - $349,219
-2,067 Reduced 39.81%
3,125 $233,000
Q4 2020

Feb 09, 2021

BUY
$125.56 - $178.74 $4,645 - $6,613
37 Added 0.72%
5,192 $885,000
Q3 2020

Nov 10, 2020

SELL
$127.12 - $172.34 $24,279 - $32,916
-191 Reduced 3.57%
5,155 $724,000
Q2 2020

Aug 13, 2020

SELL
$93.0 - $171.7 $221,991 - $409,847
-2,387 Reduced 30.87%
5,346 $857,000
Q1 2020

May 11, 2020

BUY
$82.38 - $131.64 $56,430 - $90,173
685 Added 9.72%
7,733 $756,000
Q4 2019

Feb 10, 2020

BUY
$76.53 - $135.58 $76,989 - $136,393
1,006 Added 16.65%
7,048 $909,000
Q3 2019

Nov 12, 2019

SELL
$72.81 - $156.91 $1,456 - $3,138
-20 Reduced 0.33%
6,042 $455,000
Q2 2019

Aug 06, 2019

SELL
$112.21 - $151.95 $14,587 - $19,753
-130 Reduced 2.1%
6,062 $921,000
Q1 2019

May 08, 2019

SELL
$106.67 - $151.68 $440,653 - $626,590
-4,131 Reduced 40.02%
6,192 $738,000
Q4 2018

Feb 08, 2019

BUY
$97.32 - $148.76 $1 Million - $1.54 Million
10,323 New
10,323 $1.13 Million

Others Institutions Holding SRPT

About Sarepta Therapeutics, Inc.


  • Ticker SRPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,567,904
  • Market Cap $10.4B
  • Description
  • Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...
More about SRPT
Track This Portfolio

Track Summit Wealth & Retirement Planning, Inc. Portfolio

Follow Summit Wealth & Retirement Planning, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Summit Wealth & Retirement Planning, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Summit Wealth & Retirement Planning, Inc. with notifications on news.